Last updated on May 2020

INCB001158 Combined With Subcutaneous (SC) Daratumumab Compared to Daratumumab SC in Relapsed or Refractory Multiple Myeloma


Brief description of study

The purpose of this study is to evaluate the safety and antitumor activity of INCB001158 in combination with daratumumab SC, compared with daratumumab SC alone, in participants with relapsed or refractory multiple myeloma.

Clinical Study Identifier: NCT03837509

Find a site near you

Start Over